Cd16 pe

Manufactured by Miltenyi Biotec

Sourced in United States

The CD16-PE is a fluorochrome-conjugated antibody that binds to the CD16 antigen, which is expressed on the surface of natural killer (NK) cells, monocytes, and granulocytes. This antibody can be used for the identification and enumeration of these cell populations in flow cytometry applications.

Automatically generated - may contain errors

Lab products found in correlation

Cd62l vioblue, by Miltenyi Biotec (3 mentions) Cd3 apc vio770, by Miltenyi Biotec (3 mentions) Cd8 viogreen, by Miltenyi Biotec (3 mentions) Cd8 apc vio770, by Miltenyi Biotec (2 mentions) Cd4 vioblue, by Miltenyi Biotec (2 mentions) Cd45ra pe, by Miltenyi Biotec (2 mentions) Cd56 pe vio770, by Miltenyi Biotec (2 mentions) Cd19 fitc, by Miltenyi Biotec (2 mentions) Ccr7 fitc, by Miltenyi Biotec (2 mentions) Cd45ro apc, by Miltenyi Biotec (2 mentions) Streptavidin pe, by Thermo Fisher Scientific (1 mentions) Annexin 5 pe, by BD (1 mentions) Cd56 pe, by BD (1 mentions) Cd3 apc, by BioLegend (1 mentions) Cd56 apc, by BioLegend (1 mentions) Streptavidin apc, by BioLegend (1 mentions) Cytoflex, by Beckman Coulter (1 mentions) Brefeldin a, by BioLegend (1 mentions) Monensin, by BioLegend (1 mentions) Facscalibur cytometer, by BD (1 mentions)

Close spelling variants of this product

PE anti-human CD16 (4 citations) PE-conjugated anti-CD16 (2 citations) Anti-CD16 PE- Vio770 (2 citations)

5 protocols using cd16 pe

Flow Cytometry Analysis of Surface Markers

Check if the same lab product or an alternative is used in the 5 most similar protocols

Flow cytometry was used for the analysis of surface marker or transgene expression. The following antibodies were used: CD3-APC (OKT3, BioLegend, San Diego, CA, USA), CD16-PE (REA423, Miltenyi), CD56-APC (AF12-7H3, BioLegend; HCD56, Miltenyi Biotec), CD56-FITC (REA196 Miltenyi), CD56-PE (B159, Becton Dickinson, BD, Heidelberg, Germany), Ganglidiomab-PE (Gangliomab-phycoerythrin (PE) monoclonal antibody was kindly provided by H. Lode and N. Siebert (46 (link)) and PE-conjugated), IgG, F(ab′)₂ (Biotin-SP-conjugated, Jackson ImmunoResearch, West Grove, PA, USA), Ganglioside GD2-APC (14G2a, BioLegend), Ganglioside GD2-PE (14G2a, BioLegend), and Annexin V-PE (BD Biosciences, Franklin Lakes, USA) and the secondary antibodies Streptavidin-APC (BioLegend) and Streptavidin-PE (eBioscience, San Diego, CA, USA). For staining of the degranulation marker CD107a, cocultures were incubated with CD107a-APC (Miltenyi) for 1 h at 37°C and 5% CO₂ with shaking. Afterward, Brefeldin A (1:1,000; BioLegend) and Monensin (1:1,000; BioLegend) were added for an additional incubation for 4 h at 37°C and 5% CO₂ with shaking. Stained cells were measured via FACSCalibur cytometer (Becton Dickinson, BD) or CytoFLEX (Beckman Coulter) and analyzed via FlowJo software (Tree Star Inc., Ashland, OR, USA).

Rudek L.S., Zimmermann K., Galla M., Meyer J., Kuehle J., Stamopoulou A., Brand D., Sandalcioglu I.E., Neyazi B., Moritz T., Rossig C., Altvater B., Falk C.S., Abken H., Morgan M.A, & Schambach A. (2021). Generation of an NFκB-Driven Alpharetroviral “All-in-One” Vector Construct as a Potent Tool for CAR NK Cell Therapy. Frontiers in Immunology, 12, 751138.

+ Open protocol

+ Expand

Flow Cytometry Immunophenotyping Panel

Check if the same lab product or an alternative is used in the 5 most similar protocols

MACSQuant Analyzer, MACSQuant Analyzer VYB (Miltenyi Biotec), or FACSCanto, LSRII (Becton Dickinson, NJ) was used to analyze cell populations by flow cytometry. The following antibody and protein conjugates were used: CD3-PE, CD3-APC-Vio770, CD4-APC, CD4-VioGreen, CD8-APC-Vio770, CD8-VioGreen, CD14-APC, CD16-PE, CD19-APC, CD20-PerCP-Vio770, CD20-PE-Vio770, CD34-APC, CD34-PE, CD45-VioBlue, CD45-VioGreen, CD45RO-PE-Vio770, CD56-PE, CD62L-VioBlue, CD95-APC, CD45-VioBlue (mouse) (all from Miltenyi Biotec); ErbB2-Fc fusion protein (R&D Systems), anti-human-IgG (Fc gamma-specific) PE (eBioscience). 7AAD staining was used for dead cell exclusion and Violet Cell Trace (Thermo Fisher) for SupT1 cell tracking.

Radek C., Bernadin O., Drechsel K., Cordes N., Pfeifer R., Sträßer P., Mormin M., Gutierrez-Guerrero A., Cosset F.L., Kaiser A.D., Schaser T., Galy A., Verhoeyen E, & Johnston I.C. (2019). Vectofusin-1 Improves Transduction of Primary Human Cells with Diverse Retroviral and Lentiviral Pseudotypes, Enabling Robust, Automated Closed-System Manufacturing. Human Gene Therapy, 30(12), 1477-1493.

+ Open protocol

+ Expand

Immunophenotyping of PBMC and T-cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Staining of cell surface markers on PBMC and T-cells was performed with CD3-APC/Vio770, CD4-Vioblue, CD8-Viogreen, CD19-FITC, CD56-PE/Vio770, CD16-PE, CD62L-Vioblue, CD45RA-PE, CD45RO-APC, and CCR7-FITC (Miltenyi, San Diego, CA; BD, Franklin Lakes, NJ). All samples were acquired on a MACSQuant Cytometry (Miltenyi) and the data analyzed with Flow Jo (Treestar, Ashland, OR).

McLaughlin L.P., Lang H., Williams E., Wright K.E., Powell A., Cruz C.R., Colberg-Poley A.M., Barese C., Hanley P.J., Bollard C.M, & Keller M.D. (2016). Human Parainfluenza Virus-3 can be Targeted by Rapidly ex vivo Expanded T-Lymphocytes. Cytotherapy, 18(12), 1515-1524.

+ Open protocol

+ Expand

Comprehensive CBMC and T Cell Immunophenotyping

Check if the same lab product or an alternative is used in the 5 most similar protocols

Staining of cell surface markers on CBMCs and T cells was performed with CD3-APC/Vio770, CD4-Vioblue, CD8-Viogreen, CD19-FITC, CD56-PE/Vio770, CD16-PE, CD62L-Vioblue, CD45RA-PE, CD45RO-APC, and CCR7-FITC (Miltenyi Biotec and BD Biosciences). 50,000 events per sample were acquired on a MACSQuant cytometer (Miltenyi), and the data were analyzed with Flow Jo (Tree Star).

Dave H., Luo M., Blaney J.W., Patel S., Barese C., Cruz C.R., Shpall E.J., Bollard C.M, & Hanley P.J. (2017). Toward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood. Molecular Therapy. Methods & Clinical Development, 5, 13-21.

+ Open protocol

+ Expand

Immunophenotyping of Whole Blood in GCA

Check if the same lab product or an alternative is used in the 5 most similar protocols

Venous blood was drawn from GCA patients into heparin-containing tubes. Whole blood immunophenotyping was performed using 7-Color Immunophenotyping kit with the following antibodies (Miltenyi Biotec, catalog #130-098-456): CD14-FITC (clone Tük4), CD56-PE (clone REA196), CD16-PE (clone REA423), CD4-PerCP (clone VIT4), CD19-PE-Vio® 770 (clone LT19), CD3-APC (clone BW264/56), CD8-APC-Vio 770 (clone BW135/80), CD45-VioBlue® (clone 5B1). Briefly, 100 μl of whole blood was incubated with 10 μl immunophenotyping reagent for 10 min in the dark, at 4°C. After incubation, whole blood was lysed using Red Blood Lysing Solution (Miltenyi Biotec, catalog #130-098-456). Neutrophil phenotyping was performed in 50 μl of whole blood, incubated for 30 min at 4°C in the dark, with the following antibodies (eBioscience): CD16-PE (clone eBioCB16; catalog #50-112-4738), CD62L-PE-Cy5 (clone DREG56; catalog #50-140-71) and CD11b-APC (clone ICRF44; catalog #17-0118-42). After incubation, samples were lysed, using Whole Blood Lysing Reagent Kit (Beckman Coulter; catalog #6602764). All samples were analyzed using flow cytometer MACSQuant Analyzer 10 (Miltenyi Biotec). Analysis of flow cytometry data was performed using MACSQuantify (Analysis Software version 2.8, Miltenyi Biotec) and FlowLogic (Flow Cytometry Analysis Package, version 7.00.0a, Invasion Software Technologies Pvt Ltd).

Kuret T., Frank-Bertoncelj M., Lakota K., Žigon P., Thallinger G.G., Kopitar A.N., Čučnik S., Tomšič M., Hočevar A, & Sodin-Šemrl S. (2022). From Active to Non-active Giant Cell Arteritis: Longitudinal Monitoring of Patients on Glucocorticoid Therapy in Combination With Leflunomide. Frontiers in Medicine, 8, 827095.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!